Editorial Perspectives On Upstream Bioprocessing

1. On The Ground At NextGen Biomed 2026 4/29/2026

   Bioprocess Online caught up with Tiffany D. Rau, Ph.D., CMC consultant and adjunct professor of biochemistry and cell biology at the University College Cork in Ireland, at Oxford Global's 2026 NextGen Biomed conference.

2. Integrate Upstream/Downstream To Reduce Development Risks And Costs 4/8/2026

   Coordinating unit operations can help reduce costs and mitigate challenges in process development. Check out these key takeaways from the Bioprocess Online Live event “Optimizing Process Development Through Upstream and Downstream Integration.”

3. On The Ground At BPI: Takeda's Amy Shaw On Scaling Cell Therapy Manufacturing 9/26/2025

   Takeda head of process development, Amy Shaw, explains what factors to consider when scaling up or scaling out cell therapy manufacturing.

4. How Lumen Is Putting The "Farm" In Biopharma 7/31/2025

   Lumen Bioscience's SVP of production and development, Craig Behnke, Ph.D., explains how the company is cutting costs and rethinking upstream manufacturing with its algae-based production platform.

5. Areas For Advancement In Peptide Manufacturing 2/27/2025

   Experts from Eli Lilly, NervGen, and Piramal Pharma Solutions discuss the myriad of ways peptide manufacturing can be improved, drawing on years of industry experience and insight.

6. GlycoNex On Challenges In Biosimilar Development, Manufacturing 1/29/2025

   In this written Q&A, GlycoNex president and CEO, Dr. Mei-Chun Yang, shares insight into the company's development of its denosumab biosimilar, SPD8. She covers the company’s approach to analytics, cell line development, scaling, and more.

7. Cell Therapy Manufacturing Trends And Advancements Continuing In 2025 12/26/2024

   In this segment of the executive roundtable discussion, our panelists reflect on recent advances in cell therapy manufacturing and discuss active areas of innovation.

8. ADCs: Leading With The Linker 12/20/2024

   Leo Marx, Ph.D., the Medicinal Chemistry Project and Bioconjugation Manager at Debiopharm, shares his company's rationale for the company's ADC development decisions and why its linker technology is the tip of the spear for those that make the cut.

9. Manufacturing CAR-T In Vivo 7/25/2024

   Manufacturing chimeric antigen receptor (CAR) T-cell therapies is a costly and complicated process. Interius BioTherapeutics is on a mission to reduce this complexity and get these therapies to patients faster — by manufacturing CAR T/NK cells in patients' bodies.

10. The Path To Producing An Insulin Biosimilar 7/17/2024

    I met with rBIO co-founder and president, Cameron Owen, as well as its CSO, Dr. Deenadayalan Bakthavatsalam, to learn about what it takes to develop an insulin biosimilar. They candidly told me about the company’s plan of execution, as well as how challenging it is to scale-up manufacturing to a commercial level (in the ballpark of several metric tons per year for insulin) — which is the company’s primary focus right now.